Postmenopausal osteoporosis treatment options fall into two groups: medicines that slow bone loss (antiresorptive drugs such as bisphosphonates and denosumab) and medicines that build new bone (anabolic drugs such as teriparatide and romosozumab). Both are combined with calcium, vitamin D, exercise, and fall prevention. The right choice depends on how high your fracture risk is, your other health conditions, and how you prefer to take medication.
This overview explains each option in plain terms, how the choices compare, and the questions worth raising with your doctor. For managing the pain that can follow a fracture, see our guide to osteoporosis pain treatment.
Why Bone Loss Speeds Up After Menopause
Bone is living tissue that is constantly remodeled. Cells called osteoclasts remove old bone, and osteoblasts lay down new bone. Estrogen restrains osteoclast activity, so when estrogen falls at menopause, removal outpaces formation and bone density drops, fastest in the first years after the final period.
Postmenopausal osteoporosis is the result: bones become thinner and structurally weaker, so they break with little force. Other risk factors include increasing age, a family history of hip fracture, low body weight, smoking, excess alcohol, long-term glucocorticoid use, and low calcium or vitamin D intake.
How Treatment Decisions Are Made
Diagnosis rests on a DXA scan (dual-energy x-ray absorptiometry) of the hip and spine, reported as a T-score, which compares your bone density with that of a healthy young adult.
| T-score | Category | Usual approach |
|---|---|---|
| -1.0 or higher | Normal | Lifestyle measures; recheck as advised |
| Between -1.0 and -2.5 | Osteopenia (low bone mass) | Treat if overall fracture risk is high |
| -2.5 or lower | Osteoporosis | Medication generally recommended |
| Any score plus a fragility fracture of hip or spine | Osteoporosis (clinical) | Medication recommended |
Doctors also use fracture-risk calculators such as FRAX, which combine age, bone density, and risk factors to estimate the ten-year chance of a major fracture. Before starting treatment, blood tests check calcium, vitamin D, kidney function, and thyroid function to exclude secondary causes of bone loss.
Medications That Slow Bone Loss
Bisphosphonates
Bisphosphonates are usually the first-line choice. They bind to bone and switch off osteoclasts. Alendronate and risedronate are taken as tablets, typically once weekly, on an empty stomach with a full glass of water while staying upright for at least 30 minutes. Ibandronate can be taken monthly, and zoledronic acid is given as a once-yearly intravenous infusion for people who cannot manage the tablet routine.
Common side effects are heartburn with tablets and a short flu-like reaction after the first infusion. Rare but important effects with long-term use are osteonecrosis of the jaw and atypical femur fractures. For this reason, many women at lower risk take a planned drug holiday after about three to five years, with reassessment afterward.
Denosumab
Denosumab is a monoclonal antibody that blocks RANK ligand, a signal osteoclasts need to form. It is injected under the skin every six months and can be used when kidney function is too low for bisphosphonates. It must not be stopped abruptly: bone loss rebounds quickly and multiple spinal fractures can follow, so a switch to another drug, usually a bisphosphonate, is planned in advance.
SERMs and Hormone Therapy
Raloxifene, a selective estrogen receptor modulator, acts like estrogen on bone and lowers the risk of spinal fractures, though it has not been shown to reduce hip fractures. It raises the risk of blood clots and can worsen hot flashes. Menopausal hormone therapy protects bone and is a reasonable option for younger postmenopausal women who also need symptom relief, but its clot, stroke, and breast cancer considerations mean it is rarely used for bone alone.
Medications That Build New Bone
Anabolic agents are generally reserved for women at very high risk: those with very low T-scores, recent fractures, or fractures despite other treatment.
- Teriparatide and abaloparatide are forms of parathyroid hormone or related peptides, given as daily self-injections, usually for up to two years.
- Romosozumab blocks sclerostin, a protein that suppresses bone formation. It is given as monthly injections for 12 months. It carries a warning about heart attack and stroke and is avoided in people with a recent history of either.
Because bone gained on anabolic drugs is lost after stopping, an antiresorptive drug is started afterward to lock in the benefit.
| Medication | Type | How it is given | Key cautions |
|---|---|---|---|
| Alendronate, risedronate | Antiresorptive | Weekly tablet | Heartburn; strict dosing routine |
| Zoledronic acid | Antiresorptive | Yearly IV infusion | Flu-like reaction; kidney function |
| Denosumab | Antiresorptive | Injection every 6 months | Do not stop without a plan |
| Raloxifene | SERM | Daily tablet | Blood clots; hot flashes |
| Teriparatide, abaloparatide | Anabolic | Daily injection | Limited treatment duration |
| Romosozumab | Anabolic | Monthly injection for 12 months | Heart attack and stroke history |
Calcium, Vitamin D, Exercise, and Fall Prevention
No drug works well without the raw materials for bone. Postmenopausal women are generally advised to get about 1,200 mg of calcium daily, preferably from food, and 800 to 1,000 IU of vitamin D. Supplements fill the gap when diet falls short.
Exercise matters for both bones and balance. Useful choices include:
- Weight-bearing activity such as brisk walking or stair climbing
- Resistance training two to three times a week
- Balance work such as tai chi
- Avoiding deep forward bending and twisting, which load the spine
Most hip fractures follow a fall, so home safety is part of treatment: good lighting, removing loose rugs, grab rails, a review of sedating medications, and regular eye checks. Stopping smoking and limiting alcohol also help. For the wider context, visit our osteoporosis guide.
When to See a Doctor
Speak to your doctor about a bone density scan if you are postmenopausal with risk factors, or if you are 65 or older. See a doctor promptly for sudden back pain, loss of height, a newly curved upper back, or any fracture from a minor fall. If you already take treatment, report jaw pain, exposed bone in the mouth, or new thigh or groin pain.
Frequently Asked Questions
Which postmenopausal osteoporosis treatment is best?
There is no single best drug. Bisphosphonates suit most women as a starting point, while those at very high risk often benefit from starting with an anabolic agent. Your doctor weighs your fracture risk, kidney function, and preferences.
How long will I need treatment?
Osteoporosis is a long-term condition, so treatment is usually reviewed every few years rather than stopped at a fixed point. Bisphosphonates may allow a break, while denosumab needs a planned transition before stopping.
Can osteoporosis be reversed?
Medications can increase bone density and substantially lower fracture risk, and anabolic drugs rebuild bone. Density rarely returns fully to normal, so the goal is preventing fractures.
Is jaw osteonecrosis common?
It is rare at osteoporosis doses. Good dental hygiene and finishing major dental work before starting treatment reduce the risk further.
Key Takeaways
- Estrogen loss after menopause accelerates bone removal, weakening the skeleton.
- Bisphosphonates and denosumab slow loss; teriparatide, abaloparatide, and romosozumab build bone.
- Calcium, vitamin D, exercise, and fall prevention support every medication.
- Treatment is individualized and reviewed over years, not months.
